文献速递MDS 与骨髓增殖性肿瘤白血病

SRSF2P95突变髓系肿瘤的共突变模式、克隆层级与克隆大小共同决定疾病表型

Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms.
PubMed 文献 · Leukemia · 2020-12-21

该研究从2663例髓系肿瘤患者中选取279例SRSF2P95突变病例,分析分子与临床特征。多因素回归显示共突变基因与临床表型相关,如JAK2/MPL与骨髓纤维化(OR=26.9)、TET2与单核细胞增多(OR=5.2)。在SRSF2-JAK2共突变者中,JAK2优势克隆总与MPN特征相关,而SRSF2优势克隆见于MDS/MPN。

要点

  • SRSF2P95突变见于MDS、MPN、MDS/MPN和AML,共突变模式可解释表型异质性。
  • JAK2/MPL共突变与骨髓纤维化强相关(OR=26.9),TET2与单核细胞增多相关(OR=5.2)。
  • 克隆层级和克隆大小影响临床表达:JAK2优势克隆对应MPN,SRSF2优势克隆对应MDS/MPN。

核心结论

  • 共突变模式、克隆大小和克隆层级共同决定SRSF2P95突变髓系肿瘤的临床表型。

研究设计与样本

  • 前瞻性队列研究,从2663例髓系肿瘤患者中选取279例SRSF2P95突变病例。

主要发现

  • 每例体细胞突变中位数为3个。
  • JAK2或MPL共突变与骨髓纤维化相关(OR=26.9)。
  • TET2共突变与单核细胞增多相关(OR=5.2)。
  • RAS通路基因共突变与白细胞增多相关(OR=5.1)。
  • STAG2、RUNX1或IDH1/2共突变与原始细胞表型(MDS或AML)相关(OR分别为3.4、1.9和2.1)。

临床怎么用

  • 对SRSF2P95突变患者应评估共突变基因、克隆大小和克隆层级以辅助表型判断。
  • JAK2优势克隆提示MPN特征,SRSF2优势克隆提示MDS/MPN特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatic mutations in splicing factor genes frequently occur in myeloid neoplasms. While SF3B1 mutations are associated with myelodysplastic syndromes (MDS) with ring sideroblasts, SRSF2P95 mutations are found in different disease categories, including MDS, myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and acute myeloid leukemia (AML). To identify molecular determinants of this phenotypic heterogeneity, we explored molecular and clinical features of a prospective cohort of 279 SRSF2P95-mutated cases selected from a population of 2663 patients with myeloid neoplasms. Median number of somatic mutations per subject was 3. Multivariate regression analysis showed associations between co-mutated genes and clinical phenotype, including JAK2 or MPL with myelofibrosis (OR = 26.9); TET2 with monocytosis (OR = 5.2); RAS-pathway genes with leukocytosis (OR = 5.1); and STAG2, RUNX1, or IDH1/2 with blast phenotype (MDS or AML) (OR = 3.4, 1.9, and 2.1, respectively). Within patients with SRSF2-JAK2 co-mutation, JAK2 dominance was invariably associated with clinical feature of MPN, whereas SRSF2 mutation was dominant in MDS/MPN. Within patients with SRSF2-TET2 co-mutation, clinical expressivity of monocytosis was positively associated with co-mutated clone size. This study provides evidence that co-mutation pattern, clone size, and hierarchy concur to determine clinical phenotype, tracing relevant genotype-phenotype associations across disease entities and giving insight on unaccountable clinical heterogeneity within current WHO classification categories.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Todisco G, Creignou M, Gallì A, et al. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia. 2020. PMID: 33349666. doi:10.1038/s41375-020-01106-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。